Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linking pharmacovigilance with pharmacogenetics.

David W J Clark1, Emma Donnelly, David M Coulter

  • 1The New Zealand Intensive Medicines Monitoring Programme (IMMP), New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, Dunedin School of Medicine, Dunedin, New Zealand. david.clark@stonebow.otago.ac.nz

Drug Safety
|December 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A primary care pharmacogenetic precision medicine pilot based on specific Māori tribal ethical frameworks and principles.

Journal of community genetics·2026
Same author

Crediting and citing Indigenous Knowledges within research.

Bioscience·2026
Same author

Allelic diversity of the pharmacogenes CYP2D6 and CYP2C19 in Māori from Te Tairāwhiti, Aotearoa New Zealand.

Frontiers in genetics·2026
Same author

Assessment of Maladaptive Exercise History Among Individuals With Eating Disorders: Validation of a Brief, Self-Report Measure.

European eating disorders review : the journal of the Eating Disorders Association·2026
Same author

Smart Total Knee Replacement: Recognition of Activities of Daily Living Using Embedded IMU Sensors and a Novel AI Model in a Cadaveric Proof-of-Concept Study.

Sensors (Basel, Switzerland)·2025
Same author

Maladaptive Exercise in People With a Lifetime History of Eating Disorders: A Multicountry Observational Study.

The International journal of eating disorders·2025

Identifying genetic factors for adverse drug reactions (ADRs) is crucial for personalized medicine. This pilot study found buccal swabs suitable for DNA collection, enabling pharmacogenetic research into ADR susceptibility.

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genetics

Background:

  • Adverse drug reactions (ADRs) incur significant personal and population costs.
  • Genetic polymorphisms can increase susceptibility to specific ADRs.
  • Identifying at-risk individuals can improve drug safety and reduce healthcare burdens.

Purpose of the Study:

  • To develop and evaluate a patient-acceptable methodology for linking pharmacogenetics with prescription event monitoring (PEM) data.
  • To assess the feasibility of using buccal swabs for DNA extraction and genotyping in a case-control study.
  • To investigate genetic variants in P-glycoprotein (P-gp) and cytochrome P450 (CYP) 2C9 associated with ADRs from cyclooxygenase-2 inhibitor use.

Main Methods:

  • A nested case-control study design was employed.

Related Experiment Videos

  • Buccal swabs were collected for DNA extraction and genotyping.
  • Patients experiencing ADRs (cases) were compared with those not experiencing ADRs (controls) matched for medication use.

    • Main Results:

    • Buccal swabs provided sufficient DNA quantity and quality for genotyping.
    • The methodology proved acceptable to the general population.
    • No significant differences in genotype distribution were found between cases and controls in this small pilot study.

    Conclusions:

    • The developed methodology is feasible for population-based pharmacogenetic studies of ADRs.
    • Further large-scale studies are needed to identify genetic risk factors for ADRs.
    • Genotyping may inform personalized drug treatment strategies and guide pre-treatment screening.